Roth Capital Has Positive Forecast for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Equities researchers at Roth Capital increased their FY2024 earnings per share estimates for shares of Tenax Therapeutics in a report released on Wednesday, November 13th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will earn ($1.16) per share for the year, up from their previous forecast of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

TENX has been the topic of several other reports. Leerink Partners initiated coverage on shares of Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price objective on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. William Blair started coverage on Tenax Therapeutics in a research note on Monday, September 30th. They set an “outperform” rating for the company. Guggenheim started coverage on Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, StockNews.com started coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $16.00.

Tenax Therapeutics Price Performance

Tenax Therapeutics stock opened at $4.87 on Monday. The company’s fifty day moving average price is $3.99 and its 200 day moving average price is $3.69. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $41.92.

Hedge Funds Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of TENX. Sphera Funds Management LTD. acquired a new stake in Tenax Therapeutics in the 3rd quarter valued at about $101,000. Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics during the 3rd quarter worth approximately $173,000. Finally, Vestal Point Capital LP purchased a new stake in shares of Tenax Therapeutics in the third quarter valued at approximately $288,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.